Sandoz Chalks Up A Third US Launch of 2019 With The First Generic Suprane
As it continues to shape its US portfolio towards more complex dosage forms, comprising biosimilars, value-added medicines and complex generics, Sandoz has announced its third launch of 2019 in the world’s largest market.
You may also be interested in...
Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
In a dramatic twist, Gilenya ANDA sponsors are now unable to launch their generic products in the US after the US Supreme Court intervened in favor of originator Novartis, superseding the US Federal Circuit.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.